#1 Clinical Trials Search in Europe

Efanesoctocog Alfa

Efanesoctocog alfa, also known as BIVV001, is an innovative drug being studied in clinical trials for the treatment of hemophilia A. This article summarizes key information about ongoing trials evaluating the safety, efficacy, and long-term effects of efanesoctocog alfa in patients with hemophilia A. The trials aim to assess how well this new therapy can prevent and treat bleeding episodes, improve joint health, and enhance quality of life for people living with this bleeding disorder.

Table of Contents

What is Efanesoctocog Alfa?

Efanesoctocog alfa is a new medication developed for the treatment of hemophilia A. It is also known by several other names, including BIVV001, Altuvoct, and Altuviiio[1]. The full scientific name of this drug is “recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein” (rFVIIIFc-VWF-XTEN)[1]. This long name describes how the medication is made and how it works in the body.

How Does Efanesoctocog Alfa Work?

Efanesoctocog alfa is a type of medication called a factor replacement therapy. In people with hemophilia A, the body doesn’t produce enough of a protein called factor VIII, which is essential for blood clotting. Efanesoctocog alfa is a laboratory-made version of factor VIII that can be given to patients to replace what their bodies are missing[2].

What makes efanesoctocog alfa unique is its design. It combines factor VIII with other proteins (Fc and von Willebrand factor) and a special molecule called XTEN. This combination helps the medication last longer in the body compared to traditional factor VIII treatments[1].

What is Efanesoctocog Alfa Used For?

Efanesoctocog alfa is primarily used to treat hemophilia A, a genetic disorder that affects blood clotting. It can be used in patients with severe hemophilia A, which means they have less than 1% of normal factor VIII levels in their blood[2].

The medication can be used in two main ways:

  1. Prophylaxis: This means taking the medication regularly to prevent bleeding episodes. Efanesoctocog alfa is often given once a week for this purpose[1].
  2. On-demand treatment: This involves using the medication to treat bleeding episodes when they occur[3].

Efanesoctocog alfa can be used in both adults and children with hemophilia A[4].

How is Efanesoctocog Alfa Given?

Efanesoctocog alfa is given as an intravenous (IV) injection, which means it’s injected directly into a vein. For prophylaxis treatment, it’s typically given once a week at a dose of 50 IU/kg (international units per kilogram of body weight)[1].

The exact dosing and frequency may vary depending on the individual patient’s needs and the severity of their condition. Some patients may receive the medication more or less frequently based on their doctor’s recommendations[3].

Effectiveness of Efanesoctocog Alfa

Clinical trials have shown promising results for efanesoctocog alfa in treating hemophilia A. Here are some key findings:

  • Reduced bleeding episodes: The medication has been shown to significantly reduce the number of bleeding episodes in patients, including joint bleeds[2].
  • Long-lasting protection: Due to its unique design, efanesoctocog alfa can maintain factor VIII levels above certain thresholds for longer periods compared to other treatments[1].
  • Improved joint health: Studies are looking at how the medication might improve long-term joint health in patients with hemophilia A[3].
  • Enhanced physical activity: Research is also investigating whether efanesoctocog alfa can help patients increase their physical activity levels[2].

Safety and Side Effects

As with any medication, efanesoctocog alfa can potentially cause side effects. Clinical trials are closely monitoring for any adverse events (unwanted effects) related to the treatment[4]. Some key safety considerations include:

  • Inhibitor development: This is when the body develops antibodies against the treatment, making it less effective. Trials are carefully watching for this[5].
  • Allergic reactions: As with many medications, there’s a potential for allergic reactions.
  • Thrombotic events: Researchers are monitoring for any unusual blood clotting events, although these are rare[5].

It’s important to note that the safety profile of efanesoctocog alfa is still being studied, and patients should discuss potential risks and benefits with their healthcare providers.

Ongoing Research

Efanesoctocog alfa is still being studied in various clinical trials. These studies are looking at different aspects of the medication, including:

  • Long-term safety and effectiveness[5]
  • Use in children under 12 years old[4]
  • Impact on physical activity and joint health[2]
  • Comparison with other factor VIII treatments[6]
  • Use in surgical settings[5]

These ongoing studies will help researchers and doctors better understand how to use efanesoctocog alfa most effectively and safely in patients with hemophilia A.

Aspect Details
Drug Name Efanesoctocog alfa (BIVV001, Altuviiio)
Condition Treated Hemophilia A (moderate to severe)
Administration Intravenous injection, typically 50 IU/kg once weekly
Key Study Objectives Long-term safety, efficacy in preventing and treating bleeds, effects on joint health, quality of life improvements
Primary Outcomes Annualized bleeding rates, inhibitor development, joint health scores
Secondary Outcomes Factor VIII activity levels, quality of life measures, pharmacokinetic parameters
Study Populations Children and adults with hemophilia A, both previously treated and newly initiated patients
Study Durations Range from 12 months to 5 years
Unique Features Extended half-life, potential for higher sustained factor VIII levels, once-weekly dosing

FAQ

  • What is efanesoctocog alfa? Efanesoctocog alfa is a recombinant factor VIII therapy designed to treat hemophilia A. It is a fusion protein that combines factor VIII with von Willebrand factor and XTEN technology to potentially extend its half-life and provide sustained factor VIII levels.
  • How is efanesoctocog alfa administered? Efanesoctocog alfa is given as an intravenous injection. In most trials, it is being studied as a once-weekly prophylactic treatment at a dose of 50 IU/kg.
  • What are the main goals of the clinical trials for efanesoctocog alfa? The trials aim to evaluate the long-term safety and efficacy of efanesoctocog alfa, its ability to prevent and treat bleeding episodes, its effects on joint health, quality of life improvements, and its pharmacokinetic properties in patients with hemophilia A.
  • Who can participate in these clinical trials? The trials are enrolling patients with moderate to severe hemophilia A, including both children and adults. Some trials focus on previously treated patients, while others are open to newly treated individuals.
  • What are some of the key outcomes being measured in these trials? Key outcomes include annualized bleeding rates, joint health scores, quality of life measures, factor VIII activity levels, number of injections needed to treat bleeds, and the occurrence of adverse events, including inhibitor development.

Ongoing Clinical Trials on Efanesoctocog Alfa

  • Study on Long-Term Effects of Efanesoctocog Alfa in Preventing Joint Bleeds in Patients with Hemophilia A

    Recruiting

    1 1 1 1
    Investigated drugs:
    Croatia Czechia France Germany Ireland Italy +2

  • Continued Access Study for Patients with Severe Hemophilia A Using Efanesoctocog Alfa

    Recruiting

    1 1 1 1
    Investigated drugs:
    Bulgaria France Germany Greece Italy The Netherlands +4

  • Study on Synovial Hypertrophy in Patients with Hemophilia A Using Efanesoctocog Alfa Prophylaxis

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Norway Spain Sweden

  • Study on Physical Activity and Joint Health in Patients Aged 12 and Older with Severe Hemophilia A Treated with Efanesoctocog Alfa for 24 Months

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Croatia Czechia France Germany +8

Glossary

  • Hemophilia A: A genetic bleeding disorder caused by a deficiency in clotting factor VIII, leading to impaired blood clotting and increased risk of bleeding.
  • Factor VIII: A protein in the blood that is essential for normal blood clotting. People with hemophilia A have low levels or dysfunctional factor VIII.
  • Prophylaxis: Regular treatment to prevent bleeding episodes in people with hemophilia.
  • Annualized Bleeding Rate (ABR): The number of bleeding episodes a person experiences in a year, used to measure the effectiveness of hemophilia treatments.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Inhibitors: Antibodies that the immune system develops against factor replacement therapy, making the treatment less effective.
  • Joint Health Score: A measure of joint damage and function in people with hemophilia, often assessed using tools like the Hemophilia Joint Health Score (HJHS).
  • Quality of Life (QoL): A measure of a person's overall well-being and ability to function in daily life, often assessed through questionnaires in hemophilia studies.
  • Target Joint: A joint that has had repeated bleeding episodes, often leading to chronic damage and dysfunction.
  • Exposure Days (EDs): The number of days a patient has received factor replacement therapy, used to measure treatment experience and risk of inhibitor development.

References

  1. https://clinicaltrials.eu/trial/continued-access-study-for-patients-with-severe-hemophilia-a-using-efanesoctocog-alfa/
  2. https://clinicaltrials.gov/study/NCT05817812
  3. https://clinicaltrials.gov/study/NCT05911763
  4. https://clinicaltrials.gov/study/NCT04759131
  5. https://clinicaltrials.gov/study/NCT04644575
  6. https://clinicaltrials.gov/study/NCT05042440